Abby Hardy, Author at BioTuesdays

Markets

Brookline starts BioCardia at buy; PT $22

Brookline Capital Markets launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $22 price target. Near the close of trading on Nov. 27, the stock was quoted at $4.55. BioCardia is a developing CardiAMP...

November 29, 2019

Developments

FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

The FDA accepted Verrica Pharmaceuticals’ (NASDAQ:VRCA) NDA for its molluscum contagiosum drug candidate, VP-102, assigning a PDUFA date of July 13, 2020. VP-102 is a topical cantharidin solution designed to treat...

November 27, 2019

Developments

Journal of Cancer paper identifies TRPV6 as a promising drug target in numerous cancers, including breast, ovarian, prostate and pancreatic cancer

The peer-reviewed Journal of Cancer published a positive review of TRPV6 as a cancer therapy target, supporting the potential of closely-held Soricimed’s lead drug candidate, SOR-C13. TRPV6 plays a role in increasing...

November 26, 2019

Feature

Artelo readies Phase 1b/2a trial of cannabinoid agonist for cancer-related anorexia

Artelo Biosciences (NASDAQ:ARTL) is gearing up to begin a UK-based Phase 1b/2a study of its cannabinoid agonist drug candidate, ART 27.13, which has the potential to stimulate cancer patients’ appetite and promote...

November 26, 2019

Developments

Aurora Bio to present systemic amyloidosis imaging tracer at ASH

Closely-held Aurora Bio will present data on its synthetic peptide radiotracer, AUR01, at the upcoming American Society for Hematology (ASH) annual meeting. AUR01 is a synthetic pan-amyloid reactive peptide being...

November 25, 2019

Executive Moves

Zenabis appoints finance expert Vincent Quan as director

Zenabis Global (TSX:ZENA) appointed Vincent Quan as a director of the company, effective immediately. Mr. Quan has more than 17 years of experience in corporate finance, specializing in the North American agriculture...

November 21, 2019

Developments

Hepion CRV431 prevents cirrhosis in severe liver disease model

Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, prevented the development of cirrhosis in a highly aggressive, preclinical model of liver disease. In the study, rats were administered...

November 20, 2019

Developments

Kiniksa Pharma’s rilonacept gets FDA breakthrough therapy designation for pericarditis

The FDA granted Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) rilonacept breakthrough therapy designation for the treatment of recurrent pericarditis. Rilonacept is a recombinant fusion protein that blocks inflammatory...

November 20, 2019

Developments

T2 Biosystems receives CE Mark for T2Resistance panel

T2 Biosystems (NASDAQ:TTOO) was granted a CE Mark for its T2Resistance panel, a diagnostic that identifies 13 of the most serious resistance genes on the Centers for Disease Control and Prevention’s antibiotic...

November 20, 2019

Developments

EMA grants Achillion danicopan PRIME designation

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received the European Medicines Agency’s (EMA) priority medicines, or PRIME, designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The EMA’s...

November 19, 2019

Author - Abby Hardy

Brookline starts BioCardia at buy; PT $22

FDA accepts Verrica Pharma’s NDA for molluscum contagiosum drug

Journal of Cancer paper identifies TRPV6 as a promising drug target in numerous cancers, including breast, ovarian, prostate and pancreatic cancer

Artelo readies Phase 1b/2a trial of cannabinoid agonist for cancer-related anorexia

Aurora Bio to present systemic amyloidosis imaging tracer at ASH

Zenabis appoints finance expert Vincent Quan as director

Hepion CRV431 prevents cirrhosis in severe liver disease model

Kiniksa Pharma’s rilonacept gets FDA breakthrough therapy designation for pericarditis

T2 Biosystems receives CE Mark for T2Resistance panel

EMA grants Achillion danicopan PRIME designation

Subscribe